A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/2006
11/30/2006	US20060269523 Produced by a lactic acid producing bacterial strain having the identifying characteristics of a strain selected from NRRL B-30514, NRRL B-30510, NRRL B-30511, and NRRL B-30645; used for reducing levels of colonization by a target bacteria in animals, especially poultry
11/30/2006	US20060269522 Sequence of natural or synthetic retroelements enabling nucleotide sequence insertion into a eukaryotic cell
11/30/2006	US20060269517 Such as acarbose or castanospermine; interferons
11/30/2006	US20060269516 Interferon-IgG fusion
11/30/2006	US20060269515 Interleukin-2 muteins
11/30/2006	US20060269514 Methods and compositions for the modulation of immune responses and cancer diseases
11/30/2006	US20060269511 Multilayer binding; lamellar surface structure containing at least two binding compounds is assembled under conditions in which the binding compounds self-regulate in or on the lamellar structure; organized mobile multifunctional conjugate (OMMC) assembly
11/30/2006	US20060269484 Medicament formulations
11/30/2006	US20060269479 Amphiphilic polymers and methods of use thereof
11/30/2006	US20060269478 Use of protein occlusion for the selective delivery of small molecules to targets
11/30/2006	US20060269477 ST receptor binding compounds and methods of using the same
11/30/2006	DE69735603T2 PTHrP Analogen PTHrP analogs
11/30/2006	CA2726759A1 Human proislet peptide, derivatives and analogs thereof, and methods of using same
11/30/2006	CA2649253A1 Cxcr4 antagonists for wound healing and re-epithelialization
11/30/2006	CA2610521A1 Modulation of the integrin-linked kinase signaling pathway provides beneficial human cardiac hypertrophy and post myocardial infarction remodeling
11/30/2006	CA2609937A1 Modulation of the integrin linked kinase signaling pathway to promote cardiac cell proliferation and self-renewal
11/30/2006	CA2609812A1 Angiotensin i-converting enzyme (ace) inhibitors
11/30/2006	CA2609811A1 Angiotensin i - converting enzyme (ace) inhibitors
11/30/2006	CA2609751A1 Compositions and methods for the treatment of cancer
11/30/2006	CA2609728A1 Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases
11/30/2006	CA2609701A1 Compositions and methods for enhancing axon regeneration
11/30/2006	CA2609456A1 Localized delivery of cardiac inotropic agents
11/30/2006	CA2609447A1 Polypeptides
11/30/2006	CA2609376A1 Lipid construct for delivery of interferon to a mammal
11/30/2006	CA2609369A1 Composition for the treatment of multiple sclerosis
11/30/2006	CA2609358A1 Nutrition formulations and methods of providing nutrition formulations
11/30/2006	CA2609271A1 Novel substrate for rpn 11 enzymatic activity
11/30/2006	CA2609188A1 Apo-2 ligand/trail formulations
11/30/2006	CA2608850A1 Methods for diagnosing epigenetic, transgenerational effects of environmental toxicants on mammalian germ-lines and treating associated diseases
11/30/2006	CA2606902A1 Insulin resistance improver
11/29/2006	EP1726659A1 Isolated dipeptides with ACE inhibitor effect
11/29/2006	EP1726656A2 Metalloproteinase-disintegrin family members: SVPH DNAs and polypeptides
11/29/2006	EP1726651A1 Method of treating muscular disorders
11/29/2006	EP1726647A1 Gene promoting vascular endothelial cell growth
11/29/2006	EP1726318A1 Medicine/gene leaching type stent
11/29/2006	EP1726311A2 Migration of hematopoietic stem cells and progenitor cells to the liver
11/29/2006	EP1726310A1 Medicine for cancer therapy
11/29/2006	EP1725904A1 Contact lenses, package systems, and method for promoting a healthy epithelium of an eye
11/29/2006	EP1725868A2 Methods of using high affinity atiii variants
11/29/2006	EP1725678A1 Differential drug sensitivity
11/29/2006	EP1725673A1 Sialytated glycoproteins-process conditions and an efficient method for their production
11/29/2006	EP1725660A2 Multiple promoter expression cassettes for simultaneous delivery of rnai agents
11/29/2006	EP1725603A2 Methods and compositions for treatment of autoimmune diseases
11/29/2006	EP1725589A1 Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
11/29/2006	EP1725586A2 Partially loaded antibodies and methods of their conjugation
11/29/2006	EP1725583A2 Methods for increasing protein polyethylene glycol (peg) conjugation
11/29/2006	EP1725580A2 Isosteric transformation
11/29/2006	EP1725579A1 Peptides derived from human bplp protein, polynucleotides coding for said peptides and antibodies directed against said peptides
11/29/2006	EP1725578A1 A novel potassium channel modulator peptide
11/29/2006	EP1725577A1 Antithrombotic compound
11/29/2006	EP1725576A2 Positive modulator of bone morphogenic protein-2
11/29/2006	EP1725262A2 Polymer-based compositions and conjugates of hiv entry inhibitors
11/29/2006	EP1725261A2 Use for interleukin-33 (il-33) and the il-33 receptor complex
11/29/2006	EP1725253A2 Medicaments and methods for treating headache
11/29/2006	EP1725252A2 Antitumour treatments with metxia-p450 and cyclophosphamide or 5t4 vaccine
11/29/2006	EP1725251A2 Selective incorporation of 5-hyroxytrypophan into proteins in mammalian cells
11/29/2006	EP1725250A2 Method for the preparation of peptide-oligonucleotide conjugates
11/29/2006	EP1725249A2 Monomethylvaline compounds capable of conjugation to ligands
11/29/2006	EP1725246A1 Compositions containing internally activated antioxidant
11/29/2006	EP1725245A2 Manganese and iron based compounds for elastogenesis and connective tissue treatment
11/29/2006	EP1725244A2 Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants
11/29/2006	EP1725233A1 Sns-595 and methods of using the same
11/29/2006	EP1725224A2 Methods and compositions comprising non-peptide small molecules that solubilize beta amyloid peptide fiber
11/29/2006	EP1725223A2 Use of antagonists of the cb1 receptor for the manufacture of a composition useful for the treatment of hepatic deseases
11/29/2006	EP1725220A1 Effervescent formulations comprising desmopressin
11/29/2006	EP1725099A2 Peptide mixtures with immunomodulatory activity
11/29/2006	EP1660525B1 Plant-derived peptides harboring water-cleaning and antimicrobial activities
11/29/2006	EP1597276A4 Therapeutic molecules
11/29/2006	EP1497656B1 Diagnosis of carcinoma using raig1 polypeptides
11/29/2006	EP1478381A4 Use of soluble gamma delta t cell receptors for regulating t cell function
11/29/2006	EP1448765A4 Matrix for the production of tissue engineered ligaments, tendons and other tissue
11/29/2006	EP1401474B1 Methods for inducing sustained immune response
11/29/2006	EP1397124B1 Use of antidiabetics for making a medicine with cicatrizing effect
11/29/2006	EP1360296B1 Method for the production of plant seed with modified fibre content and modified seed coat
11/29/2006	EP1353953B1 Mu-1, member of the cytokine receptor family
11/29/2006	EP1301614B1 Codon-optimized papilloma virus sequences
11/29/2006	EP1299724B1 Synthetic peptide for neurological disorders
11/29/2006	EP1290164B1 Human twik-8 molecules and uses thereof
11/29/2006	EP1220911B1 P-glycoproteins and uses thereof
11/29/2006	EP1218403B1 Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery
11/29/2006	EP1206529B1 UDP-N-ACETYLGLUCOSAMINE: GALACTOSE-BETA 1,3-N-ACETYLGALACTOSAMINE-ALPHA-R/(GlcNAc to GalNAc) BETA 1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE, C2GnT3
11/29/2006	EP1198251B1 Combination of an anti-ep-cam antibody with a chemotherapeutic agent
11/29/2006	EP1189936B1 Use of eif4e binding agents in therapy
11/29/2006	EP1158993B1 Bacterial membrane fractions with adjuvant effect
11/29/2006	EP1117692B1 Tie2 agonist antibodies
11/29/2006	EP1114861B1 Ly6h gene
11/29/2006	EP1092027B1 Therapeutic and diagnostic domain 1 beta 2 gp1 polypeptides and methods of using same
11/29/2006	EP1088066B1 Antisense oligonucleotide constructs based on beta-arabinofuranose and its analogues
11/29/2006	EP1012281B1 Human leukocyte calcium activated potassium channel polypeptide
11/29/2006	EP0994721B1 Nerve growth factor as a vaccine adjuvant
11/29/2006	EP0973541B1 Use of histons for the production of medicaments
11/29/2006	EP0948624B1 Mutants of streptococcal toxin a and methods of use
11/29/2006	EP0837936B1 New immunoregulatory protein lst-1
11/29/2006	EP0821695B1 Antibody purification by low-ph hydrophobic interaction chromatography
11/29/2006	EP0788546B1 Nematode-extracted serine protease inhibitors and anticoagulant proteins
11/29/2006	EP0719336B1 Modified plant viruses as vectors of heterologous peptides
11/29/2006	EP0631505B2 Use of a peptide
11/29/2006	EP0605501B2 Use of presynaptic neurotoxin for the treatment of cerebral palsy
11/29/2006	EP0556292B2 Hepatitis c virus asialoglycoproteins
11/29/2006	CN1871351A Novel fungal proteins and nucleic acids encoding same

1 ... 1177 1178 1179 1180 1181 1182 1183 1184 1185 1186 1187 1188 1189 1190 1191 1192 1193 1194 1195 1196 1197 ... 3163